Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects. by Gramaglia, E et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Gramaglia E;Ramella Gigliardi V;Olivetti I;Tomelini M;Belcastro S;Calvi
E;Dotta A;Ghigo E;Benso A;Broglio F. Impact of short-term treatment with
benzodiazepines and imidazopyridines on glucose metabolism in healthy
subjects.. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. 37
(2) pp: 203-206.
DOI: 10.1007/s40618-013-0016-y
The publisher's version is available at:
http://link.springer.com/content/pdf/10.1007/s40618-013-0016-y
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/142750
1 
 
Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose 
metabolism in healthy subjects 
 
 
E. Gramaglia, V. Ramella Gigliardi, I. Olivetti, M. Tomelini, S. Belcastro, E. Calvi, A. Dotta, E. Ghigo, 
A. Benso, F. Broglio 
 
Division of Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, A.O. 
Città Della Salute e Della Scienza, San Giovanni Battista, Molinette Hospital University of Turin 
Turin Italy 
  
2 
 
Abstract 
Aim: In the last years there has been a progressive reduction of the average duration of sleep and 
an increase in the incidence of sleep disturbances. At the same time, an increase of the incidence 
of the metabolic syndrome has been described, partly attributable to the progressive worsening of 
dietary habits and the increase in sedentary lifestyle. Recent studies suggest that adequate sleep is 
essential to maintain good glucose metabolism and sleep disturbances may contribute to the 
manifestation of the metabolic syndrome. Benzodiazepines (BZ), such as brotizolam, and 
imidazopyridines, such as zolpidem, are frequently used as hypnotics but their potential impact on 
glucose metabolism has never been evaluated so far. 
Methods: In 12 healthy volunteers [age (mean ± SEM) 38.3 ± 8.1 years; body mass index (BMI) 
21.9 ± 0.8 kg/m2] we studied glucose and insulin responses to oral glucose tolerance test (OGTT, 
75 g) before and after 15 days treatment with brotizolam 0.25 mg/day or zolpidem 10 mg/day. 
Results: Brotizolam increased glucose delta area under curve response to the OGTT by 122 % (p < 
0.01) and zolpidem by 86 % (p < 0.01) without significant variations of insulin levels, suggesting an 
impact on insulin sensitivity and/or insulin secretion. 
Conclusions: This study suggests that BZ and imidazopyridines have a rapid glucometabolic effect 
that is detectable as early as after 15 days treatment. 
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Introduction 
In the last years there has been a progressive reduction of the average duration of sleep and an 
increase in the incidence of sleep disturbances (both general impairment of sleep quality and 
increase of specific disorders like obstructive sleep apnea syndrome) [1, 2]. 
At the same time there has been an increase of incidence of metabolic syndrome due to the 
coexistence of alterations in glucose metabolism, lipid metabolism and hypertension that act 
simultaneously in increasing cardiovascular risk [3]. 
Although the most important cause of increase of metabolic syndrome is lifestyle change, 
epidemiological and experimental studies suggest that sleep plays an important role in modulating 
glucose metabolism, the neuroendocrine control of food intake and blood pressure. As a 
consequence, sleep disturbances may contribute to the manifestation of the metabolic syndrome 
[3]. The discovery of the association between sleep disturbances and the different components of 
metabolic syndrome offers important insights into the treatment of sleep disturbances for the 
prevention of cardiovascular risks [1]. 
It is well known that benzodiazepines (BZ), molecules that bind γ-aminobutyric acid A (GABA A) 
receptor in the central nervous system, are largely used as anxiolytics and hypnotics, and produce 
an increase in sleep length but also significant alterations in sleep structure [4, 5]. BZ reduce sleep 
latency, the number of awakenings, the wakefulness state and the length of stage 1, 3, and 4 while 
they increase that of stage 2 and modify the latency and length of rapid eyes movements (REM) 
sleep [4, 5]. These alterations seem not to be caused by imidazopyridines, new molecules used as 
hypnotics able to bind GABA A receptor with a specific selectivity for the BZ 1/omega one subtype 
[6–8]. These molecules reduce sleep latency and extend total sleep time but have little effects on 
sleep structure [6–8]. 
At present, despite their frequent use in clinical practice, the impact of these molecules on glucose 
metabolism has never been evaluated so far. 
Based on this background, the aim of our study was to investigate in vivo in humans, the effects of 
a short-term modulation of GABA system, known to be involved in the control of insulin secretion 
[9–15], through the administration of brotizolam, a benzodiazepine, and zolpidem, an 
imidazopyridine, on the insulin and the glucose response to an oral glucose tolerance test (OGTT) 
in healthy subjects. 
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Materials and methods 
Twelve healthy volunteers [4 men and 8 women; age (mean ± SEM) 38.3 ± 8.1 years; BMI 21.9 ± 
0.8 kg/m2] were studied. None of them had a personal or family history of diabetes mellitus or a 
personal history of sleep disorders according to the Pittsburgh sleep quality index (PSQI). All the 
subjects gave their written informed consent to participate in the study, which had been approved 
by the Ethical Committee of the University of Turin. All subjects underwent the two following 
testing sessions in random order at least 1 month apart: 
    (a) 15 days treatment with brotizolam 0.25 mg/day at 2200 hours. 
    (b) 15 days treatment with zolpidem 10 mg/day at 2200 hours.      
Diet and physical exercise were standardized for at least 15 days before and during all the sessions 
tests. 
 
On day 0 and on day 16 of each session, all the subjects underwent an oral glucose tolerance test 
(OGTT; glucose 75 g p.o.). After overnight fasting, OGTT was performed in the morning at 08:30–
09:00 a.m., 30 min later an indwelling catheter had been placed into an antecubital vein of the 
forearm kept patent by slow infusion of isotonic saline solution. 
 
Blood samples were collected every 15 min from time −15 min up to +120 min. Glucose and insulin 
levels were assayed at each time point in all the sessions. 
 
Plasma glucose levels (mmol/l) were measured by the glucose oxidase colorimetric method 
(Glucofix; Menarini Diagnostics, Florence, Italy). 
 
Serum insulin levels (pmol/l) were measured in duplicate by immunoradiometric assay (INSIK-5; 
SORIN Biomedica, Saluggia, Italy). Sensitivity of the assay: 17.36 ± 2.08 pmol/l. Inter- and intra-
assay coefficients of variation (CV): 6.2–10.8 and 5.5–10.6 %. 
 
Glucose and insulin levels are expressed as mean ± SEM absolute levels or delta area under curve 
(∆AUC) calculated by trapezoidal integration. Matsuda index was calculated as in [16]. The 
statistical analysis was carried out using non-parametric Mann–Whitney test, as appropriate. 
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Results 
As expected, in all the experimental conditions, OGTT induced a significant increase (p < 0.01) of 
both glucose and insulin levels. Glucose and insulin responses to OGTT performed on day 0 were 
similar (p n.s.) between the two sessions (Fig. 1). Notably, 15 days treatment with brotizolam 
increased glucose ∆AUC response to OGTT by 122 % (166.63 ± 31.72 mmol/l min on day 16 vs. 
89.67 ± 33.08 mmol/l min on day 0; p < 0.01) while zolpidem by 86 % (182.96 ± 29.44 mmol/l min 
on day 16 vs. 126.04 ± 32.11 mmol/l min on day 0; p < 0.01), whereas no statistical differences 
were observed in terms of insulin responses both after brotizolam (28673.13 ± 4311.59 pmol/l min 
on day 16 vs. 23637.31 ± 3653.76 pmol/l min on day 0) and after zolpidem (40019.17 ± 9027.81 
pmol/l min on day 16 vs. 40915.77 ± 9096.56 pmol/l min on day 0) (Fig. 2). Based on the OGTT 
data, insulin sensitivity calculated by Matsuda index decreased by 12 % after brotizolam (4.8 ± 0.4 
on day 16 vs. 5.6 ± 0.5 on day 0) and by 4 % after zolpidem (5.2 ± 0.6 on day 16 vs. 5.2 ± 0.7 on day 
0), although both these variations did not attain statistical difference. 
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Discussion 
Our paper describes for the first time that a benzodiazepine (i.e., brotizolam) and an 
imidazopyridine (i.e., zolpidem) affect glucose metabolism as early as after 15 days treatment. 
These effects include an elevation of AUC glucose during OGTT, without significant variations in 
insulin secretion, consistent with alteration in insulin sensitivity and/or insulin secretion. 
The pathophysiological mechanisms underlying these effects are at present unknown, but an 
indirect effect due to an alteration of sleep structure seems unlikely, as the increase in glucose 
response to OGTT was present even after zolpidem treatment that is known not to impair sleep 
architecture [6–8]. 
The hypothesis of a direct influence of brotizolam and zolpidem on insulin sensitivity is suggestive, 
though there are no data in the literature describing a direct effect of GABA on this parameter. A 
double-blind placebo-controlled study showed that administration of clonazepam during a 
frequently sampled intravenous glucose tolerance test reduced the acute insulin response in a 
concentration-dependent manner. The authors speculated that insulin sensitivity and glucose 
disposal could be influenced by the muscle relaxing action of this drug, but this hypothesis has 
never been definitely proved so far [16]. Similarly, the variations on Matsuda index we observed 
should be interpreted cautiously, though the lack of statistical significance could be related to the 
small number of subjects studied [17, 18]. 
Similarly, a potential GABA-mediated activation of counter-regulatory responses has theoretically 
to be excluded as BZ that have been demonstrated to inhibit the activity of the autonomous 
nervous system, glucagon and growth hormone secretion, lipolysis and glycogenolysis [19]. 
A potential impact of GABA activation on insulin secretion should be taken into account carefully. 
In fact, GABA has been reported to affect insulin secretion though both inhibitory and stimulatory 
effects have been reported in different experimental models [9–15]. Actually, the apparent 
absence of a compensatory increase of insulin secretion to the enhanced glucose ΔAUC could 
support the hypothesis of a partial inhibition of beta-cell responsiveness to glucose load after 
brotizolam or zolpidem pretreatment. Nevertheless, we have to take into account that in this 
study the absence of statistical differences in terms of insulin response in both test sessions could 
be related to the small number of subjects included in our protocol. 
 
Notably, in none of our healthy subjects, neither brotizolam nor zolpidem led the glucose response 
to OGTT to the range of impaired glucose tolerance (IGT). Though many studies suggest that acute 
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administration of these drugs determines glycemic disregulation, there are no data in the 
literature on the long-term effect of BZ as a risk factor for diabetes. Further research is then 
needed to investigate the metabolic effect of a long-term treatment with the aforementioned 
drugs in subjects with a high personal risk to develop diabetes. 
In conclusion, this study shows that BZ and imidazopyridines have a rapid glucometabolic effect in 
healthy human volunteers that is detectable as early as after 15 days treatment. These results, 
though preliminary, may suggest the need for screening for the risk of developing diabetes 
mellitus before starting a long-term treatment with these drugs and a periodic metabolic follow up 
during the treatment. 
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Figures  
 
 
 
 
 
Fig. 1 Mean (±SEM) glucose and insulin responses to OGTT performed before and after 15 days 
treatment with brotizolam (0.25 mg/day) or zolpidem (10 mg/day) 
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Fig. 2 Mean (±SEM) ∆AUC glucose and insulin responses to OGTT before and after 15 days 
treatment with brotizolam (0.25 mg/day) or zolpidem (10 mg/day) (five pointed star) = p < 0.01 
